158 related articles for article (PubMed ID: 36572067)
1. Quality over quantity; eosinophil activation status will deepen the insight into eosinophilic diseases.
Hilvering B; Koenderman L
Respir Med; 2023 Feb; 207():107094. PubMed ID: 36572067
[TBL] [Abstract][Full Text] [Related]
2. Experimental Modeling of Eosinophil-Associated Diseases.
Upparahalli Venkateshaiah S; Manohar M; Kandikattu HK; Mishra A
Methods Mol Biol; 2021; 2241():275-291. PubMed ID: 33486743
[TBL] [Abstract][Full Text] [Related]
3. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
Wechsler ME; Klion AD; Paggiaro P; Nair P; Staumont-Salle D; Radwan A; Johnson RR; Kapoor U; Khokhar FA; Daizadeh N; Chen Z; Laws E; Ortiz B; Jacob-Nara JA; Mannent LP; Rowe PJ; Deniz Y
J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2695-2709. PubMed ID: 35636689
[TBL] [Abstract][Full Text] [Related]
4. Eosinophils and eosinophilic immune dysfunction in health and disease.
Jackson DJ; Akuthota P; Roufosse F
Eur Respir Rev; 2022 Mar; 31(163):. PubMed ID: 35082127
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of type 2 disease status in a real-world population of difficult to manage asthma using historic electronic healthcare records of blood eosinophil counts.
Azim A; Newell C; Barber C; Harvey M; Knight D; Freeman A; Fong WCG; Dennison P; Haitchi HM; Djukanovic R; Kurukulaaratchy R; Howarth P
Clin Exp Allergy; 2021 Jun; 51(6):811-820. PubMed ID: 33528864
[TBL] [Abstract][Full Text] [Related]
6. Eosinophils in Health and Disease: A State-of-the-Art Review.
Wechsler ME; Munitz A; Ackerman SJ; Drake MG; Jackson DJ; Wardlaw AJ; Dougan SK; Berdnikovs S; Schleich F; Matucci A; Chanez P; Prazma CM; Howarth P; Weller PF; Merkel PA
Mayo Clin Proc; 2021 Oct; 96(10):2694-2707. PubMed ID: 34538424
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of Intestinal Tissue Eosinophils: Potential Considerations for Next-Generation Eosinophil-Targeting Strategies.
Masterson JC; Menard-Katcher C; Larsen LD; Furuta GT; Spencer LA
Cells; 2021 Feb; 10(2):. PubMed ID: 33671475
[TBL] [Abstract][Full Text] [Related]
8. From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
Pavord ID; Bel EH; Bourdin A; Chan R; Han JK; Keene ON; Liu MC; Martin N; Papi A; Roufosse F; Steinfeld J; Wechsler ME; Yancey SW
Allergy; 2022 Mar; 77(3):778-797. PubMed ID: 34402066
[TBL] [Abstract][Full Text] [Related]
9. The Role and Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review.
Eng SS; DeFelice ML
Clin Rev Allergy Immunol; 2016 Apr; 50(2):140-58. PubMed ID: 26797962
[TBL] [Abstract][Full Text] [Related]
10. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
[TBL] [Abstract][Full Text] [Related]
11. Serum eosinophil cationic protein as a marker of eosinophilic inflammation in asthma.
Niimi A; Amitani R; Suzuki K; Tanaka E; Murayama T; Kuze F
Clin Exp Allergy; 1998 Feb; 28(2):233-40. PubMed ID: 9515598
[TBL] [Abstract][Full Text] [Related]
12. Airway hyperresponsiveness: first eosinophils and then neuropeptides.
Kraneveld AD; Folkerts G; Van Oosterhout AJ; Nijkamp FP
Int J Immunopharmacol; 1997; 19(9-10):517-27. PubMed ID: 9637348
[TBL] [Abstract][Full Text] [Related]
13. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait.
David B; Bafadhel M; Koenderman L; De Soyza A
Thorax; 2021 Feb; 76(2):188-195. PubMed ID: 33122447
[TBL] [Abstract][Full Text] [Related]
14. Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?
Van Hulst G; Bureau F; Desmet CJ
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576313
[TBL] [Abstract][Full Text] [Related]
15. Degranulation patterns of eosinophil granulocytes as determinants of eosinophil driven disease.
Erjefält JS; Greiff L; Andersson M; Adelroth E; Jeffery PK; Persson CG
Thorax; 2001 May; 56(5):341-4. PubMed ID: 11312400
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD.
Negewo NA; McDonald VM; Baines KJ; Wark PA; Simpson JL; Jones PW; Gibson PG
Int J Chron Obstruct Pulmon Dis; 2016; 11():1495-504. PubMed ID: 27445469
[TBL] [Abstract][Full Text] [Related]
18. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
19. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
Nagase H; Ueki S; Fujieda S
Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
[TBL] [Abstract][Full Text] [Related]
20. Systemic biomarkers of eosinophilic chronic rhinosinusitis.
Ho J; Earls P; Harvey RJ
Curr Opin Allergy Clin Immunol; 2020 Feb; 20(1):23-29. PubMed ID: 31688152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
